Medvi, a GLP-1 telehealth company founded by Matthew Gallagher and his brother, generated $401 million in 2025 sales and is on track for $1.8 billion in 2026 revenue — with exactly two human employees. The New York Times profiled the company this week, revealing how AI handles nearly every corporate function from customer service to compliance.
What Medvi Actually Looks Like
The two Gallagher brothers serve as the company’s only employees. AI systems handle customer service interactions, marketing campaigns, operational logistics, regulatory compliance documentation, and most business functions that would typically require hundreds of staff at this revenue scale.
For context, traditional telehealth companies generating comparable revenue — like Hims & Hers ($1.5B in 2025 revenue) — employ over 4,000 people. Medvi achieves a similar output with a workforce 2,000x smaller.
Which AI Tools Power the Operation
While the NYT profile didn’t detail every tool, the company’s tech stack reportedly includes:
- Customer service: AI chatbots handling patient inquiries, prescription follow-ups, and appointment scheduling
- Compliance: Automated regulatory monitoring and documentation generation
- Marketing: AI-generated content, ad optimization, and customer acquisition
- Operations: Automated fulfillment coordination with pharmacy partners
The brothers focus on strategic decisions, pharmacy partnerships, and the small number of edge cases AI can’t resolve.
Is This the Future of Business?
Medvi sits in a specific niche — telehealth for GLP-1 weight loss drugs like Ozempic and Wegovy — where demand is enormous and the product is relatively standardized. That combination makes it unusually well-suited to AI automation. A consulting firm or a construction company couldn’t replicate this model.
But the core insight is directional: revenue-per-employee ratios are about to become the most important metric in business. If two people can generate $1.8 billion in a favorable niche, the staffing assumptions underlying most business plans are already outdated.
The Medvi story also raises regulatory questions. The FDA and state medical boards haven’t caught up to the idea that a two-person company can serve millions of patients. Telehealth oversight was designed for organizations with compliance departments, medical directors, and quality assurance teams — all roles AI now fills at Medvi.
The Broader Pattern
Medvi isn’t the only ultra-lean AI company. Recent research shows most people follow AI recommendations without question, which partly explains how AI-driven customer service can scale so effectively. The GLP-1 market itself is projected to reach $150 billion by 2030, according to Goldman Sachs.
The question isn’t whether more Medvi-style companies will emerge — they will. The question is how fast industries restructure around the possibility that a two-person team with the right AI stack can outperform a 500-person company in specific domains.
